Of course, many chronic conditions run in families, but family history alone doesn't guarantee that a child will develop one ...

From myopia (nearsightedness) to chronic dryness and digital eye strain, ophthalmologists are reporting a spike in vision issues among youth across urban and rural India. Dr Mubashir Parkar, MBBS, DNB ...

Even in the case of uncomplicated infections, the body prepares itself early on for the possibility of a more severe course ... activity altogether as the disease progresses.

3 Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Barcelona, Spain 4 Primary Care Research Institute Jordi Gol, Girona, Spain Objective To examine the association ...

Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease.

The Company expects to have topline data from 2 other trials assessing the effect of reproxalap on dry eye disease symptoms ... ocular therapy suitable for chronic administration to have ...

Reproxalap, a reactive aldehyde species modulator, is approved for dry eye disease, reducing ocular ... used a dry eye chamber and assessed chronic administration, meeting its primary endpoint.

Burlacu and colleagues conducted a retrospective study of 64 adults with moderate to severe thyroid eye disease who were treated with IV glucocorticoids for 12 weeks according to European Group on ...

Stress is one of the leading causes of headaches. Tension in the neck, shoulders, and scalp can trigger tension headache Taking pain relief medications too frequently can lead to rebound headaches ...

He was immediately put on eye drops and advised to follow the 20-20-20 rule -- "taking a 20-second break every 20 minutes to look at something 20 feet away," the doctor said.

Graves disease had a similar phenotype at presentation but a more severe clinical course when isolated than when part of autoimmune polyglandular syndrome. Despite similarities in biochemical and ...

Kodiaq Sciences (NASDAQ:KOD), a biotechnology company focused on developing treatments for eye diseases, finds itself at a critical juncture as it navigates through clinical trials and financial ...